Study details
Enrolling now
Phase 3 Extension Trial to Evaluate Long-Term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)
Novartis Pharmaceuticals
NCT IDNCT06133972ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
550
Study length
about 7.9 years
Ages
12–100
Locations
21 sites in AL, CA, CO +9
What this study is about
Researchers are testing the long-term safety and tolerability of ianalumab in people with systemic lupus erythematosus who have already taken it as part of a previous trial. It will last for 2887 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Ianalumab
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
monoclonal antibody
Endpoints
Primary: Number of treatment-emergent Adverse events/Serious Adverse events
Body systems
Immune